Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRSP vs ACAD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACAD Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

ACAD Overall Winner 6-Pillar Tally: CRSP 1 – 5 ACAD Matrix Metrics: CRSP 4 – 6 ACAD

As of Nov 16, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over CRISPR Therapeutics AG (CRSP) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CRSP carries a Unified Composite Score of 44.7/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin), whereas ACAD carries 42.0/100 (HOLD) at $19.07 (17.8x Forward P/E, 10.2% operating margin).

  • Composite vs. Pillar Nuance: While CRSP currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. ACAD 42.0/100 HOLD), ACAD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (10.2% vs. -2058.6% operating margin) and revenue trajectory (+22.8% vs. +1325.1% YoY).
  • Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.6); meanwhile ACAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRSP vs ACAD
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
TTM Revenue $25M
Forward P/E 23.4x
Beta / 30D Vol 1.85β · 60% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 25.0 Fund 52.0 Flow 68.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.6%), weak momentum, RSI 30
RSI-14: 29.6 · SMA20: $48.84 · SMA50: $51.79
ACAD NASDAQ Head-to-Head Winner
Acadia Pharmaceuticals Inc.
Pharmaceutical Preparations
$19.07
+1.71% 1D
Market Cap $3.1B
TTM Revenue $1.20B
Forward P/E 17.8x
Beta / 30D Vol 0.11β · 93% Vol
Unified Composite Score
42.0 / 100 HOLD
Tech 43.0 Fund 52.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.8%), weak momentum, RSI 44
RSI-14: 44.0 · SMA20: $19.82 · SMA50: $21.61

6-Pillar Scorecard Institutional Category Breakdown (CRSP 1 – 5 ACAD)

Columns: Metric · CRSP · ACAD
1. Valuation Multiples ACAD
Forward P/E 23.4x 17.8x
Trailing P/E 23.4x 8.6x
PEG Ratio N/M N/M
EV / Revenue N/M 2.4x
2. Growth & Scale CRSP
Revenue Growth (YoY) +1325.1% +22.8%
Earnings Growth (YoY) +0.0% -26.2%
TTM Revenue (USD) $25M $1.20B
Market Cap $4.1B $3.1B
3. Profitability & Quality ACAD
Gross Margin N/A 63.9%
Operating Margin -2058.6% 10.2%
Net Profit Margin 0.0% 30.1%
Return on Equity (ROE) -25.6% 31.4%
4. Balance Sheet & Cash Flow ACAD
Cash Generation (TTM) -$378M $181M
Cash Flow Margin N/A 15.0%
Net Cash / Leverage $588M Net Debt (0.47x D/E) $251M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ACAD
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 97.8% (52nd %ile) 42.6% (4th %ile)
Put/Call OI Skew 0.65x (Call-Skewed) 0.33x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat ACAD
OpEx & R&D Intensity N/A 53.7% of Rev ($646M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRSP (4) vs ACAD (6)
Institutional Metric CRSP ACAD Criterion Row Edge
Market Capitalization
Scale
$4.1B $3.1B Larger Scale CRSP
Trailing P/E Ratio
Valuation
23.4x 8.6x Lower Multiple ACAD
Forward P/E Ratio
Valuation
23.4x 17.8x Lower Multiple ACAD
Revenue Growth (YoY)
Growth
+1325.1% +22.8% Higher Growth CRSP
Operating Margin (TTM)
Profitability
-2058.6% 10.2% Higher Margin ACAD
Net Profit Margin
Profitability
0.0% 30.1% Higher Margin ACAD
Return on Equity (ROE)
Capital Efficiency
-25.6% 31.4% Higher ROE ACAD
52-Week Range Position
Momentum
1% ($40–$63) 21% ($16–$31) Stronger Trend ACAD
Beta / 30D Volatility
Risk Regime
1.85β · 60% Vol 0.11β · 93% Vol Lower Realized Risk CRSP
Unified Institutional Score
Composite Signal
44.7 / 100 (HOLD) 42.0 / 100 (HOLD) Higher Composite CRSP
Trailing 12M Revenue (USD)
Operating Scale
$25M $1.20B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 63.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$378M ($588M Net Debt (0.47x D/E)) $181M ($251M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACAD +17.28 pp
CRSP: -17.54% · ACAD: -0.26%
3M Horizon CRSP +13.48 pp
CRSP: -23.33% · ACAD: -36.81%
6M Horizon ACAD +8.54 pp
CRSP: -16.37% · ACAD: -7.83%
1Y Horizon ACAD +1.21 pp
CRSP: -20.54% · ACAD: -19.33%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CRSP Revenue ACAD Revenue CRSP Op. Margin ACAD Op. Margin Margin Leader
FY2018 $0M $220M -5087.8% -110.6% ACAD
FY2019 $290M $340M 16.1% -72.7% CRSP
FY2020 $0M $440M -49295.5% -64.9% ACAD
FY2021 $910M $480M 40.8% -35.2% CRSP
FY2022 $0M $520M -56190.4% -43.2% ACAD
FY2023 $370M $730M -60.0% -10.1% ACAD
FY2024 $40M $960M -1250.4% 24.1% ACAD
FY2025 $0M $1.07B -18933.6% 9.8% ACAD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRSP BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 97.8%
IV Percentile 52nd %ile
Put/Call OI Skew 0.65x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CRSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ACAD BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 42.6%
IV Percentile 4th %ile
Put/Call OI Skew 0.33x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact ACAD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRSP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.1B market capitalization and -2058.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ACAD Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $3.1B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment 53.7% of Rev ($646M)
90D Engineering Disclosures 0 Published

Investor FAQ CRSP vs ACAD Key Questions & Quantitative Answers

As of Nov 16, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over CRISPR Therapeutics AG (CRSP) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CRSP carries a Unified Composite Score of 44.7/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin), whereas ACAD carries 42.0/100 (HOLD) at $19.07 (17.8x Forward P/E, 10.2% operating margin). Composite vs. Pillar Nuance: While CRSP currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. ACAD 42.0/100 HOLD), ACAD captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (10.2% vs. -2058.6% operating margin) and revenue trajectory (+22.8% vs. +1325.1% YoY). Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.6); meanwhile ACAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRSP leads the Growth & Scale pillar: CRSP posts +1325.1% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -2058.6% operating margin), compared with ACAD at +22.8% YoY revenue growth and -26.2% YoY earnings growth on $1.20B TTM revenue (63.9% gross margin, 10.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CRSP cumulative revenue shifted -86.2% while ACAD shifted +386.4%. In operating R&D and SG&A reinvestment, CRSP deploys N/A (0 90-day corporate R&D disclosures) versus 53.7% of Rev ($646M) (0 disclosures) for ACAD.

ACAD screens cheaper on headline valuation multiples. CRSP trades at 23.4x Forward P/E, 23.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ACAD trades at 17.8x Forward P/E, 8.6x Trailing P/E, N/M PEG, and 2.4x EV/Revenue (15.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRSP (-25.6% ROE) versus ACAD (31.4% ROE) capital efficiency.

In options market volatility and institutional positioning, CRSP carries 97.8% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.65x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.85β · 60% Vol realized risk). By comparison, ACAD carries 42.6% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.33x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.11β · 93% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.